Evaluation of current and upcoming therapies in oral mucositis prevention

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1751-1770

  Wu, Jerry C ^a   Beale, Keola K ^b   Ma, Joseph D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

amifostine; dihydropyrimidine dehydrogenase; glutamine; glutathione S transferase; growth factors; laser phototherapy; oral mucositis; palifermin

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTIINFLAMMATORY AGENT; ATL 104; BENZYDAMINE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CG53135 05; CHLORHEXIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXTRO METHIONINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; MELPHALAN; MITOGENIC AGENT; MRX 1024; PALIFERMIN; PHYTOHEMAGGLUTININ L; PLACEBO; POLAPREZINC; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT INTESTINAL TREFOIL FACTOR; RIFAMPICIN; RSPONDIN 1; THIOTEPA; UNCLASSIFIED DRUG; VELAFERMIN; ZINC SULFATE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; AMYLASE BLOOD LEVEL; ANOREXIA; BURN; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CRYOTHERAPY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHEMA; FACE EDEMA; FACE ERYTHEMA; FATIGUE; FEVER; FLUSHING; HEAD AND NECK CANCER; HEALING; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MORNING DOSAGE; MOUTH HYGIENE; MOUTH INFLAMMATION; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PARESTHESIA; PATHOGENESIS; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; QUALITY OF LIFE; RADIATION DOSE; RASH; REVIEW; RHINITIS; SIDE EFFECT; TASTE DISORDER; TONGUE SWELLING; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

DIETARY SUPPLEMENTS; HUMANS; SEVERITY OF ILLNESS INDEX; STOMATITIS; THERAPIES, INVESTIGATIONAL;

EID: 78650198312     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.133     Document Type: Review

References (170)

1. Peterson DE, Bensadoun RJ, Roila F: Management of oral and gastrointestinal mucositis: ESMO clinical recommendations. Ann. Oncol. 20(Suppl. 4), 174-177 (2009).
2. Cheng KK: Oral mucositis, dysfunction, and distress in patients undergoing cancer therapy. J. Clin. Nurs. 16(11), 2114-2121 (2007).
3. Trotti A, Bellm LA, Epstein JB et al.: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol. 66(3), 253-262 (2003).
4. Murphy BA, Beaumont JL, Isitt J et al.: Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy J. Pain Symptom Manage. 38(4), 522-532 (2009).
5. Madeya ML: Oral complications from cancer therapy: Part 1- pathophysiology and secondary complications. Oncol. Nurs. Forum 23(5), 801-807 (1996).
6. Elting LS, Cooksley CD, Chambers MS, Garden AS: Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int. J. Radiat. Oncol. Biol. Phys. 68(4), 1110-1120 (2007).
7. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
8. Sonis ST, Elting LS, Keefe D et al.: Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(Suppl. 9), 1995-2025 (2004).
9. Blijlevens N, Schwenkglenks M, Bacon P et al.: Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or beam conditioning chemotherapy - European Blood and Marrow Transplantation Mucositis Advisory Group. J. Clin. Oncol. 26(9), 1519-1525 (2008).
10. Keefe DM, Schubert MM, Elting LS et al.: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5), 820-831 (2007).
11. Sonis ST: Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 45(12), 1015-1020 (2009).
12. Motzer RJ, Escudier B, Oudard S et al.: Effcacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
13. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
14. Sonis S, Treister N, Chawla S, Demetri G, Haluska F: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116(1), 210-215 (2009).
15. Nonzee NJ, Dandade NA, Patel U et al.: Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113(6), 1446-1452 (2008).
16. Russo G, Haddad R, Posner M, Machtay M: Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 13(8), 886-898 (2008).
17. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fuorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 332(14), 901-906 (1995).
18. Scully C, Sonis S, Diz PD: Oral mucositis. Oral. Dis. 12(3), 229-241 (2006).
19. Sonis ST: Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34(1), 39-43 (1998).
20. Sonis ST: The pathobiology of mucositis. Nat. Rev. Cancer 4(4), 277-284 (2004).
21. Sonis S, Haddad R, Posner M et al.: Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 43(3), 289-300 (2007).
22. Denham JW, Hauer-Jensen M: The radiotherapeutic injury-a complex 'wound'. Radiother. Oncol. 63(2), 129-145 (2002).
23. Paris F, Fuks Z, Kang A et al.: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293(5528), 293-297 (2001).
24. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA: Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22(37), 5813-5827 (2003).
25. Sonis ST: The biologic role for nuclear factor-kb in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit. Rev. Oral Biol. Med. 13(5), 380-389 (2002).
26. Bartke N, Hannun YA: Bioactive sphingolipids: metabolism and function. J. Lipid Res. 50(Suppl.), S91-S96 (2009).
27. Obeid LM, Linardic CM, Karolak LA, Hannun YA: Programmed cell death induced by ceramide. Science 259(5102), 1769-1771 (1993).
28. Lin CC, Tseng HW, Hsieh HL et al.: Tumor necrosis factor-a induces MMP-9 expression via p42/p44 mapk, jnk, and nuclear factor-kB in A549 cells. Toxicol. Appl. Pharmacol. 229(3), 386-398 (2008).
29. Al-Dasooqi N, Gibson RJ, Bowen JM, Keefe DM: Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother. Pharmacol. 64(1), 1-9 (2009).
30. Morvan FO, Baroukh B, Ledoux D et al.: An engineered biopolymer prevents mucositis induced by 5-fuorouracil in hamsters. Am. J. Pathol. 164(2), 739-746 (2004).
31. Donnelly JP, Bellm LA, Epstein JB, Sonis ST, Symonds RP: Antimicrobial therapy to prevent or treat oral mucositis. Lancet Infect. Dis. 3(7), 405-412 (2003).
32. van der Velden WJ, Blijlevens NM, Feuth T, Donnelly JP: Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplant. 43(1), 55-60 (2009).
33. Worthington HV, Clarkson JE, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev. 4, CD000978 (2007).
34. Tran KT, Griffth L, Wells A: Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 12(3), 262-268 (2004).
35. Salmela MT, Pender SL, Karjalainen-Lindsberg ML, Puolakkainen P, Macdonald TT, Saarialho-Kere U: Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand. J. Gastroenterol. 39(11), 1095-1104 (2004).
36. Mashimo H, Wu DC, Podolsky DK, Fishman MC: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274(5285), 262-265 (1996).
37. Beck PL, Wong JF, Li Y et al.: Chemotherapy-and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 126(3), 796-808 (2004).
38. Kjellev S: The trefoil factor family - small peptides with multiple functionalities. Cell. Mol. Life Sci. 66(8), 1350-1369 (2009).
39. Clevers H: Wnt/b-catenin signaling in development and disease. Cell 127(3), 469-480 (2006).
40. Kuhnert F, Davis CR, Wang HT et al.: Essential requirement for wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of dickkopf-1. Proc. Natl Acad. Sci. USA 101(1), 266-271 (2004).
41. Pinto D, Gregorieff A, Begthel H, Clevers H: Canonical wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev. 17(14), 1709-1713 (2003).
42. Kim KA, Kakitani M, Zhao J et al.: Mitogenic infuence of human R-spondin1 on the intestinal epithelium. Science 309(5738), 1256-1259 (2005).
43. Zhao J, Kim KA, Abo A: Tipping the balance: modulating the wnt pathway for tissue repair. Trends Biotechnol. 27(3), 131-136 (2009).
44. Finch PW, Rubin JS: Keratinocyte growth factor/fbroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv. Cancer Res. 91, 69-136 (2004).
45. Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT: Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc. Natl Acad. Sci. USA 89(15), 6896-6900 (1992).
46. Finch PW, Pricolo V, Wu A, Finkelstein SD: Increased expression of keratinocyte growth factor messenger RNA associated with infammatory bowel disease. Gastroenterology 110(2), 441-451 (1996).
47. Blijlevens N, Sonis S: Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann. Oncol. 18(5), 817-826 (2007).
48. Lindquist SF, Hickey AJ, Drane JB: Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy. J. Prosthet. Dent. 40(3), 312-314 (1978).
49. Peterson DE, Overholser CD Jr: Dental management of leukemic patients. Oral Surg. Oral Med. Oral Pathol. 47(1), 40-42 (1979).
50. Dudjak LA: Mouth care for mucositis due to radiation therapy. Cancer Nurs. 10(3), 131-140 (1987).
51. Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M: Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur. J. Cancer B. Oral Oncol. 30B(2), 93-97 (1994).
52. da Silva Santos PS, Coracin FL, Barros JC, Dulley FL, Nunes FD, Magalhaes MG: Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin. Transplant. (2010) (Epub ahead of print).
53. Shieh SH, Wang ST, Tsai ST, Tseng CC: Mouth care for nasopharyngeal cancer patients undergoing radiotherapy. Oral Oncol. 33(1), 36-41 (1997).
54. Kenny SA: Effect of two oral care protocols on the incidence of stomatitis in hematology patients. Cancer Nurs. 13(6), 345-353 (1990).
55. McGuire DB, Correa ME, Johnson J, Wienandts P: The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 14(6), 541-547 (2006).
56. Mahood DJ, Dose AM, Loprinzi CL et al.: Inhibition of fuorouracil-induced stomatitis by oral cryotherapy. J. Clin. Oncol. 9(3), 449-452 (1991).
57. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fuorouracil-induced stomatitis. Eur. J. Cancer B. Oral Oncol. 30B(4), 234-236 (1994).
58. Rocke LK, Loprinzi CL, Lee JK et al.: A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fuorouracil-related stomatitis. Cancer 72(7), 2234-2238 (1993).
59. Aisa Y, Mori T, Kudo M et al.: Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 13(4), 266-269 (2005).
60. Mori T, Hasegawa K, Okabe A et al.: Effcacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation. Int. J. Hematol. 88(5), 583-587 (2008).
61. Dumontet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffer B: Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 14(3), 492-494 (1994).
62. Svanberg A, Birgegard G, Ohrn K: Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy - a randomized controlled trial. Support Care Cancer 15(10), 1155-1161 (2007).
63. Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F: Ice pops to prevent melphalan-induced stomatitis. Lancet 347(9016), 1691-1692 (1996).
64. Lilleby K, Garcia P, Gooley T et al.: A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 37(11), 1031-1035 (2006).
65. Ethyol® (amifostine) for injection, package insert. Ben Venue, Inc, Bedford, OH, USA
66. Hwang WY, Koh LP, Ng HJ et al.: A randomized trial of amifostine as a cytoprotectant for patients receiving 59. myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 34(1), 51-56 (2004).
67. Mell LK, Movsas B: Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine. Expert. Opin. Drug Metab. Toxicol. 4(10), 1341-1350 (2008).
68. Spencer A, Horvath N, Gibson J et al.: Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant. 35(10), 971-977 (2005).
69. Lorusso D, Ferrandina G, Greggi S et al.: Phase III multicenter randomized trial of amifostine as cytoprotectant in frst-line chemotherapy in ovarian cancer patients. Ann. Oncol. 14(7), 1086-1093 (2003).
70. Brizel DM, Wasserman TH, Henke M et al.: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18(19), 3339-3345 (2000).
71. Bourhis J, De Crevoisier R, Abdulkarim B et al.: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(5), 1105-1108 (2000).
72. Koukourakis MI, Kyrias G, Kakolyris S et al.: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. J. Clin. Oncol. 18(11), 2226-2233 (2000).
73. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 52(3), 739-747 (2002).
74. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A: Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 64(3), 684-691 (2006).
75. Buntzel J, Kuttner K, Frohlich D, Glatzel M: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann. Oncol. 9(5), 505-509 (1998). (Pubitemid 28270638)
76. Thorstad WL, Chao KS, Haughey B: Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin. Oncol. 31(6 Suppl. 18), 8-12 (2004).
77. Suntharalingam M, Jaboin J, Taylor R et al.: The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin. Oncol. 31(6 Suppl. 18), 2-7 (2004).
78. Ozsahin M, Betz M, Matzinger O et al.: Feasibility and effcacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Arch. Otolaryngol. Head Neck Surg. 132(2), 141-145 (2006).
79. Anne PR, Machtay M, Rosenthal DI et al.: A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(2), 445-452 (2007).
80. Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O: Effcacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 69(5), 1361-1368 (2007).
81. Rubin JS, Bottaro DP, Chedid M et al.: Keratinocyte growth factor. Cell Biol. Int. 19(5), 399-411 (1995).
82. Farrell CL, Bready JV, Rex KL et al.: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality Cancer Res. 58(5), 933-939 (1998).
83. Dorr W, Noack R, Spekl K, Farrell CL: Modifcation of oral mucositis by keratinocyte growth factor: single radiation exposure. Int. J. Radiat. Biol. 77(3), 341-347 (2001).
84. Rosen LS, Abdi E, Davis ID et al.: Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fuorouracil-based chemotherapy. J. Clin. Oncol. 24(33), 5194-5200 (2006).
85. Spielberger R, Stiff P, Bensinger W et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351(25), 2590-2598 (2004).
86. Stiff PJ, Emmanouilides C, Bensinger WI et al.: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. 24(33), 5186-5193 (2006).
87. Brizel DM, Murphy BA, Rosenthal DI et al.: Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J. Clin. Oncol. 26(15), 2489-2496 (2008).
88. Meropol NJ, Somer RA, Gutheil J et al.: Randomized Phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J. Clin. Oncol. 21(8), 1452-1458 (2003).
89. Kepivance™ (palifermin), package insert. Amgen Inc. Thousand Oaks, CA, USA.
90. Kim JH, Chu FC, Lakshmi V, Houde R: Benzydamine HCL, a new agent for the treatment of radiation mucositis of the oropharynx. Am. J. Clin. Oncol. 9(2), 132-134 (1986).
91. Sonis ST, Clairmont F, Lockhart PB, Connolly SF: Benzydamine HCL in the management of chemotherapy-induced mucositis. I. Pilot study. J. Oral. Med. 40(2), 67-71 (1985).
92. Epstein JB, Silverman S Jr, Paggiarino DA et al.: Benzydamine HCL for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92(4), 875-885 (2001).
93. Kazemian A, Kamian S, Aghili M, Hashemi FA, Haddad P: Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur. J. Cancer Care (Engl.) 18(2), 174-178 (2009).
94. Epstein JB, Stevenson-Moore P, Jackson S, Mohamed JH, Spinelli JJ: Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse. Int. J. Radiat. Oncol. Biol. Phys. 16(6), 1571-1575 (1989).
95. Kin-Fong Cheng K, Ka Tsui Yuen J: A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs. 29(5), 423-430 (2006).
96. Tantum verde, mouth spray solution, package insert. Angelini, Rome, Italy.
97. Peterson DE, Barker NP, Akhmadullina LI et al.: Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fuorouracil-based chemotherapy. J. Clin. Oncol. 27(26), 4333-4338 (2009).
98. Servold SA: Growth factor impact on wound healing. Clin. Podiatr. Med. Surg. 8(4), 937-953 (1991).
99. Brown GL, Curtsinger L 3rd, Brightwell JR et al.: Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J. Exp. Med. 163(5), 1319-1324 (1986).
100. Brown GL, Curtsinger LJ, White M et al.: Acceleration of tensile strength of incisions treated with EGF and TGF-b. Ann. Surg. 208(6), 788-794 (1988).
101. Ino M, Ushiro K, Ino C, Yamashita T, Kumazawa T: Kinetics of epidermal growth factor in saliva. Acta Otolaryngol. Suppl. 500, 126-130 (1993).
102. Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST: The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89(11), 2258-2265 (2000).
103. Lee SW, Jung KI, Kim YW, Jung HD, Kim HS, Hong JP: Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1172-1178 (2007).
104. Girdler NM, McGurk M, Aqual S, Prince M: The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. A Phase I clinical trial. Am J. Clin. Oncol. 18(5), 403-406 (1995).
105. Wu HG, Song SY, Kim YS et al.: Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective Phase 2 multi-institutional clinical trial. Cancer 115(16), 3699-3708 (2009).
106. Schuster M W, Shore TB, Harpel JG et al.: Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Support Care Cancer 16(5), 477-483 (2008).
107. Jeffers M, McDonald WF, Chillakuru RA et al.: A novel human fbroblast growth factor treats experimental intestinal infammation. Gastroenterology 123(4), 1151-1162 (2002).
108. Alvarez E, Gerlach VL, Gerwien RW et al.: Single-dose prevention or short-term treatment with fbroblast growth factor-20 (cg53135-05)reduces the severity and duration of oral mucositis. Support Cancer Ther. 2(2), 122-127 (2005).
109. Hammarstrom S, Hammarstrom ML, Sundblad G, Arnarp J, Lonngren J: Mitogenic leukoagglutinin from Phaseolus vulgaris binds to a pentasaccharide unit in N-acetyllactosamine-type glycoprotein glycans. Proc. Natl Acad. Sci. USA 79(5), 1611-1615 (1982).
110. Phytohemagglutinin-L (PHA-L), package insert. Roche Applied Science, Mannheim, Germany.
111. Linderoth A, Biernat M, Prykhodko O et al.: Induced growth and maturation of the gastrointestinal tract after Phaseolus vulgaris lectin exposure in suckling rats. J. Pediatr. Gastroenterol. Nutr. 41(2), 195-203 (2005).
112. Hunter A, Mahendra P, Wilson K et al.: Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 43(7), 563-569 (2009).
113. Rezaei N, Aghamohammadi A, Nourizadeh M et al.: Cytokine production by activated T cells in common variable immunodefciency. J. Investig. Allergol. Clin. Immunol. 20(3), 244-251 (2010).
114. Kim KA, Zhao J, Andarmani S et al.: R-spondin proteins: a novel link to b-catenin activation. Cell Cycle 5(1), 23-26 (2006).
115. Zhao J, Kim KA, De Vera J, Palencia S, Wagle M, Abo A: R-spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical wnt/b-catenin pathway. Proc. Natl Acad. Sci. USA 106(7), 2331-2336 (2009).
116. Chung YL, Lee MY, Pui NN: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30(8), 1387-1397 (2009).
117. Buphenyl® (sodium phenylbutyrate) tablets, package insert. Ucyclyd Pharma Inc, Scottsdale, AZ, USA.
118. Blanchard F, Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of infammatory diseases? Drug Discov. Today 10(3), 197-204 (2005).
119. Hamstra DA, Eisbruch A, Naidu MU et al.: Pharmacokinetic analysis and Phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer. Clin. Cancer Res. 16(9), 2666-2676 (2010).
120. Vale JA, Meredith TJ, Goulding R: Treatment of acetaminophen poisoning. The use of oral methionine. Arch. Intern. Med. 141(3 Spec No), 394-396 (1981).
121. Campbell KC, Rybak LP, Meech RP, Hughes L: D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear. Res. 102(1-2), 90-98 (1996).
122. Reser D, Rho M, Dewan D et al.: L- and D-methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology 20(5), 731-748 (1999).
123. Vuyyuri SB, Hamstra DA, Khanna D et al.: Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin. Cancer Res. 14(7), 2161-2170 (2008).
124. Mester E, Spiry T, Szende B: Effect of laser rays on wound healing. Bull. Soc. Int. Chir. 32(2), 169-173 (1973).
125. Kana JS, Hutschenreiter G, Haina D, Waidelich W: Effect of low-power density laser radiation on healing of open skin wounds in rats. Arch. Surg. 116(3), 293-296 (1981).
126. Braverman B, McCarthy RJ, Ivankovich AD, Forde DE, Overfeld M, Bapna MS: Effect of helium-neon and infrared laser irradiation on wound healing in rabbits. Lasers Surg. Med. 9(1), 50-58 (1989).
127. Enwemeka CS: Laser biostimulation of healing wounds: specifc effects and mechanisms of action. J. Orthop. Sports Phys. Ther. 9(10), 333-338 (1988).
128. Pourreau-Schneider N, Soudry M, Franquin JC et al.: Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fuorouracil: a preliminary report. J. Natl Cancer Inst. 84(5), 358-359 (1992).
129. Genot-Klastersky MT, Klastersky J, Awada F et al.: The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies. Support Care Cancer 16(12), 1381-1387 (2008).
130. Cowen D, Tardieu C, Schubert M et al.: Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 38(4), 697-703 (1997).
131. Antunes HS, de Azevedo AM, da Silva Bouzas LF et al.: Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 109(5), 2250-2255 (2007).
132. Schubert MM, Eduardo FP, Guthrie KA et al.: A Phase III randomized double-blind placebo-controlled clinical trial to determine the effcacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 15(10), 1145-1154 (2007).
133. Chor A, Torres SR, Maiolino A, Nucci M: Low-power laser to prevent oral mucositis in autologous hematopoietic stem cell transplantation. Eur. J. Haematol. 84(2), 178-179 (2009).
134. Bensadoun RJ, Franquin JC, Ciais G et al.: Low-energy HE/NE laser in the prevention of radiation-induced mucositis. A multicenter Phase III randomized study in patients with head and neck cancer. Support Care Cancer 7(4), 244-252 (1999).
135. Simoes A, Eduardo FP, Luiz AC et al.: Laser phototherapy as topical prophylaxis against head and neck cancer radiotherapy-induced oral mucositis: comparison between low and high/low power lasers. Lasers Surg. Med. 41(4), 264-270 (2009).
136. Windmueller HG: Glutamine utilization by the small intestine. Adv. Enzymol. Relat. Areas Mol. Biol. 53, 201-237 (1982).
137. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat. Rev. 29(6), 501-513 (2003).
138. Klimberg VS, Salloum RM, Kasper M et al.: Oral glutamine accelerates healing of the small intestine and improves outcome after whole abdominal radiation. Arch. Surg. 125(8), 1040-1045 (1990).
139. Klimberg VS, Souba WW, Dolson DJ et al.: Prophylactic glutamine protects the intestinal mucosa from radiation injury Cancer 66(1), 62-68 (1990).
140. Fox AD, Kripke SA, De Paula J, Berman JM, Settle RG, Rombeau JL: Effect of a glutamine-supplemented enteral diet on methotrexate -induced enterocolitis. JPEN J. Parenter Enteral. Nutr. 12(4), 325-331 (1988).
141. Skubitz KM, Anderson PM: Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J. Lab. Clin. Med. 127(2), 223-228 (1996).
142. Anderson PM, Schroeder G, Skubitz KM: Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer 83(7), 1433-1439 (1998).
143. Peterson DE, Jones JB, Petit RG 2nd: Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 109(2), 322-331 (2007).
144. Petit R, Shinal E, French C: AES-14 facilitates rapid intracellular transport of high levels of L-glutamine in mucosal epithelial cells. Presented at: 36th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, 20-23 May 2000.
145. Anderson PM, Ramsay NK, Shu XO et al.: Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant. 22(4), 339-344 (1998).
146. Coghlin Dickson TM, Wong RM, Negrin RS et al.: Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J. Parenter. Enteral. Nutr. 24(2), 61-66 (2000).
147. Huang EY, Leung SW, Wang CJ et al.: Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 46(3), 535-539 (2000).
148. Cerchietti LC, Navigante AH, Lutteral MA et al.: Double-blinded, placebo-controlled trial on intravenous L-alanyl- L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 65(5), 1330-1337 (2006).
149. Federico A, Iodice P, Federico P, Del Rio A, Mellone MC, Catalano G: Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur. J. Clin. Nutr. 55(4), 293-297 (2001).
150. Maitra AK, Dorani B: Role of zinc in post-injury wound healing. Arch. Emerg. Med. 9(2), 122-124 (1992).
151. Rostan EF, DeBuys HV, Madey DL, Pinnell SR: Evidence supporting zinc as an important antioxidant for skin. Int. J. Dermatol. 41(9), 606-611 (2002).
152. Mitsuhashi H, Suemaru K, Li B, Cui R, Araki H: Evaluation of topical external medicine for 5-fuorouracil-induced oral mucositis in hamsters. Eur. J. Pharmacol. 551(1-3), 152-155 (2006).
153. Ertekin MV, Koc M, Karslioglu I, Sezen O: Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 167-174 (2004).
154. Lin LC, Que J, Lin LK, Lin FC: Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int. J. Radiat. Oncol. Biol. Phys. 65(3), 745-750 (2006).
155. Watanabe T, Ishihara M, Matsuura K, Mizuta K, Itoh Y: Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. Int. J. Cancer 127(8), 1984-1990 (2010).
156. Elting LS, Shih YC, Stiff PJ et al.: Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of Phase 3 trial results. Biol. Blood Marrow Transplant. 13(7), 806-813 (2007).
157. Rotolo S, Ceccarelli S, Romano F, Frati L, Marchese C, Angeloni A: Silencing of keratinocyte growth factor receptor restores 5-fuorouracil and tamoxifen effcacy on responsive cancer cells. PLoS One 3(6), E2528 (2008).
158. Brake R, Starnes C, Lu J et al.: Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Mol. Cancer Res. 6(8), 1337-1346 (2008).
159. Di Pietro G, Magno LA, Rios-Santos F: Glutathione S-transferases: an overview in cancer research. Expert. Opin. Drug Metab. Toxicol. 6(2), 153-170 (2010).
160. Hahn T, Zhelnova E, Sucheston L et al.: A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol. Blood Marrow Transplant 16(6), 801-808 (2010).
161. Moyer AM, Salavaggione OE, Hebbring SJ et al.: Glutathione S-t ran sfe rase T1 and M1: gene sequence variation and functional genomics. Clin. Cancer Res. 13(23), 7207-7216 (2007).
162. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong SY: Glutathione-S- transferase genotypes infuence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet. Cytogenet. 198(1), 40-46 (2010).
163. Kuhne A, Sezer O, Heider U et al.: Population pharmacokinetics of melphalan and glutathione S-t ran sfe rase polymorphisms in relation to side effects. Clin. Pharmacol. Ther. 83(5), 749-757 (2008).
164. Schwab M, Zanger UM, Marx C et al.: Role of genetic and nongenetic
165. Raida M, Schwabe W, Hausler P et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5́-splice donor site of intron 14 in patients with severe 5-fuorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res. 7(9), 2832-2839 (2001).
166. Morel A, Boisdron-Celle M, Fey L et al.: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fuorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006).
167. van Kuilenburg AB, Haasjes J, Richel DJ et al.: Clinical implications of dihydropyrimidine dehydrogenase (DPD) defciency in patients with severe 5-fuorouracil-associated toxicity: Identifcation of new mutations in the DPD gene. Clin. Cancer Res. 6(12), 4705-4712 (2000).
168. van Erp NP, Eechoute K, van der Veldt AA et al.: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol. 27(26), 4406-4412 (2009).
169. Bogunia-Kubik K, Polak M, Lange A: TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant. 32(6), 617-622 (2003).
170. Sakamoto K, Oka M, Yoshino S et al.: Relation between cytokine promoter gene polymorphism and toxicity of 5-fuorouracil plus cisplatin chemotherapy. Oncol. Rep. 16(2), 381-387 (2006).